Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment

• Published in: Archives of rheumatology Vol. 35; no. 2; pp. 300 - 302
• Main Authors: Yazisiz, Veli, Ucar, Ismail, Aslan, Bengisu, Erbasan, Funda, Terzioglu, Mustafa Ender
• Format: Journal Article
• Language: English
• Published: Istanbul Turkish League Against Rheumatism 01.06.2020; Prof Sebnem Ataman, President Turkish League Against Rheumatism
• Subjects: Abdomen; Arthritis; Authorship; Clinical trials; Crohns disease; Cytokines; Immunology; Inflammatory bowel disease; Interleukins; Letter; Marketing; Monoclonal antibodies; Patients; Psoriasis; Ulcers
• ISSN: 2148-5046; 1309-0291; 2618-6500; 1309-0283
• DOI: 10.46497/ArchRheumatol.2020.7555

A pooled safety analysis showed that events of IBD were uncommon with secukinumab treatment.8 Post-marketing registries have found 18 new-onset IBD patients among 1,721 patients using secukinumab.9 Also, the incidence of new-onset IBD in biologic databases was higher in patients treated with ixekizumab, another IL-17A inhibitor.9 Interleukin-21 and IL-22 produced by T-helper 17 (Th17) cells have protective and regenerative effects on epithelial cells.10 Th17 cells can contribute to CD progression by dysregulating mucosal immunological response.11 While Th17 cells have been shown to contribute to the progression of CD, it is interesting that IL-17 blockade drugs have been ineffective in the treatment of that disease. [...]it should be kept in mind that before starting an IL-17 antagonist on a patient with spondyloarthropathy, signs of subclinical bowel disease should be carefully investigated. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.